Covidien宣布就剥离制药业务计划提交Form 10注册声明

DUBLIN--(BUSINESS WIRE)--Feb. 1, 2013-- Covidien plc (NYSE: COV) today announced the initial filing by Mallinckrodt plc of a Form 10 Registration Statement with the U.S. Securities and Exchange Commission (SEC) in connection with Covidien’s previously announced plan to spin off its Pharmaceuticals business.

"The filing of the Form 10 Registration Statement is an important milestone in our ongoing separation process," said José E. Almeida, Chairman, President and CEO. "As two distinct businesses, Covidien and Mallinckrodt will be better positioned to capitalize on significant growth opportunities and provide greater focus on their respective businesses and strategic priorities. We remain on track to complete the spin-off by mid-2013."

As previously announced, Covidien intends to spin off its Pharmaceuticals business through a distribution ofMallinckrodt shares which is expected to be tax-free to U.S. shareholders, except for cash received in lieu of fractional shares.

Completion of the transaction is subject to a number of conditions, including effectiveness of the registration statement filed with the SEC, receipt of a favorable ruling from the Internal Revenue Service and an opinion from tax counsel and other customary conditions. The transaction also remains subject to final approval of the Covidien Board of Directors. Assuming all conditions are met, the separation is expected to occur at the end of the second calendar quarter of 2013.

The Form 10 Registration Statement contains important information about Mallinckrodt and the separation, including an overview of the businesses in which Mallinckrodt will operate and of the company's competitive strengths, strategies and risk factors.

A copy of the Form 10 is available at www.sec.gov. Additionally, the Form 10 can be found in the Investor Relations section of Covidien’s website at http://investor.covidien.com.

ABOUT COVIDIEN

Covidien is a leading global healthcare products company that creates innovative medical solutions for better patient outcomes and delivers value through clinical leadership and excellence. Covidien manufactures, distributes and services a diverse range of industry-leading product lines in three segments: Medical Devices, Pharmaceuticals andMedical Supplies. With 2012 revenue of $11.9 billion, Covidien has 43,000 employees worldwide in 70 countries, and its products are sold in over 140 countries. Please visit www.covidien.com to learn more about our business.